Alnylam Pharma (ALNY) Tops Q2 EPS by 91c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $298.76 -4.49%
EPS Growth %: +403.1%
Financial Fact:
Loss from operations: -92.45M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: +403.1%
Financial Fact:
Loss from operations: -92.45M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $0.32, $0.91 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $773.69 million versus the consensus estimate of $643.2 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple suing OpenAI over alleged misappropriation of trade secrets
- Faraday Future registers up to 62M shares for resale
- Occidental Petroleum releases Q2 2026 earnings considerations
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
